-
After a median follow-up of 5 years, the aromatase inhibitor, anastrozole decreased the incidence of breast cancer in high-risk postmenopausal women by 53% compared to women receiving a placebo.
-
Synopsis: In this study, the authors evaluated and refined previously published risk stratification for locoregional failure (LF) by applying it to a multicenter patient cohort.
-
In a trial comparing chemotherapy alone to chemotherapy plus bevacizumab in the treatment of patients with platinium-resistant ovarian cancer, the combination resulted in improved response rates and progression-free survival (PFS) and without a high rate of added toxicity. Whether bevacizumab alone would provide comparable improvements was not assessed but remains an important question for future trials.
-
In an international, randomized, non-inferiority trial, bendamustine-rituximab proved comparable in overall response rate when compared with R-CHOP or R-CVP in the management of indolent NHL and mantle cell lymphoma. Progression free and overall survival comparisons remain to be determined. Notably, toxicity profiles were significantly different, with higher rates of reported nausea and vomiting with BR and neuropathy and alopecia with R-CHOP/R-CVP.
-
Breast cancer survivors participating in a 12-week yoga program reported decreased fatigue, increased vitality, and improved sleep on multiple scoring systems, but no impact on depressive symptoms. Increased time spent doing yoga led to greater improvements in inflammation, mood, and fatigue.
